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Abstract  
BACKGROUND: Global tuberculosis (TB) epidemic is being driven to an increasing extent by the emergence and 
spread of drug-resistant strains of Mycobacterium tuberculosis complex (MTBC). We present a case of primary 
multidrug-resistant tuberculosis (MDR-TB), highlighting Macedonian MDR-TB management issues. 
CASE REPORT: A 39-year old previously healthy Caucasian male, with no previous history of TB or close 
contact to TB, was admitted in referral TB-hospital due to respiratory bleeding. Chest X-ray revealed opacity with 
cavernous lesions in the right upper lobe. Sputum samples showed no presence of acid-fast bacilli (AFB) on 
fluorescence microscopy, but molecular tests (real-time PCR-based assay and multiplex PCR-based reverse 
hybridisation Line Probe Assay) confirmed the presence of MTBC, also revealing rifampicin and isoniazid 
resistance and absence of resistance to second-line anti-tubercular drugs. The strain was considered multidrug-
resistant, lately confirmed by conventional methods in liquid and solid culture. Following the protocol of the World 
Health Organization, we started the longer treatment of MDR-TB comprised of at least five effective anti-
tubercular drugs. Due to patient’s extreme non-adherence, we had to delay and modify the regimen (i.e. omitting 
parenteral aminoglycoside) and to discharge him from the hospital a month after directly observed therapy (DOT) 
in negative pressure room. As there is no legal remedy in our country regarding involuntary isolation, our patient 
continued the regimen under ambulatory control of referral TB-hospital. Ignoring the risk of additional acquisition 
of drug resistance and prolonged exposure of the community to MDR-TB strain - for which he was repeatedly 
advised - he decided to cease the therapy six months after beginning. 
CONCLUSION: The benefit of molecular tests in the early diagnosis of TB and drug resistance is unequivocal for 
adequate treatment of resistant forms of TB. Whole genome sequencing ensures additional knowledge of 
circulating strains and their resistance patterns. These are essentials of effective TB control programs and can 
provide evidence to medical and legal authorities for more active policies of screening, involuntary confinement 
and compliance with therapy, and alternative modalities for successful treatment, as a part of infection control. 
 
 
 
 
 
Introduction 
 
Global tuberculosis (TB) epidemic is being 
driven to an increasing extent by the emergence and 
spread of drug-resistant strains of Mycobacterium 
tuberculosis [1] [2]. Multidrug-resistant TB (i.e. TB 
resistant to rifampicin and isoniazid, MDR-TB) 
presents major risk to global tuberculosis control, due 
to the great discrepancy between real and estimated 
burden, long-term (18-24 months) and expensive 
treatment, with less effective and more toxic drugs 
then first-line treatment, and low treatment success 
rate (54% globally) [3] [4] [5] [6]. 
According to World Health Organization 
(WHO), of the estimated 600,000 people newly 
eligible for MDR-TB treatment in 2016 (490,000 cases 
of MDR-TB and an additional 110,000 with rifampicin-
resistant TB, RR-TB), only 129,689 (22%) received 
appropriate treatment. Of these MDR-TB cases, an 
estimated 6.2% will develop extensively resistant 
tuberculosis (i.e. MDR-TB plus resistance to at list one 
quinolone and list one parenteral anti-tubercular drug, 
XDR-TB) [6]. Hence, timely and accurate diagnosis of 
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MDR-TB, particularly among new TB-cases, is 
essential to initiate appropriate treatment, which can 
prevent further amplification of drug resistance and 
break the chain of infection [7]. 
Exciting developments in the field of 
molecular diagnosis of TB and drug resistance have 
led to an era in which rapid testing for TB and 
rifampicin (RIF) resistance, almost always associated 
with MDR-TB, have been rolled out on a global scale 
[8] [9]. The WHO has recommended molecular testing 
as the standard of care for diagnosis of TB and MDR-
TB around the world [8] [10] [11]. Furthermore, 
recently a new shortened treatment has been 
introduced for selected MDR-TB patients in terms to 
the redintegrate optimal balance of adherence and 
cure of MDR-TB patients, with adverse drug events 
and overall cost of the treatment [12]. 
The Republic of Macedonia is a country with a 
low total number of notified cases of MDR-TB over a 
ten years period, low incidence of MDR- TB 
(0.28/100,000 in 2016) and continuously declining TB 
incidence [6] [13]. However, this enviable 
epidemiological setting interpreted regarding intensive 
migration processes in the recent years should raise 
the vigilance for future. 
Here we present a case of primary resistant 
MDR-TB and most likely imported from abroad, that is 
particularly useful in highlighting the Macedonian 
MDR-TB management issues. 
 
 
Case Report 
 
A 39-year old previously healthy Caucasian 
male, a smoker, employed as a professional driver on 
international truck transport, sought medical care at 
the local hospital due to respiratory bleeding. After 
initial assessment and supportive treatment, he was 
referred as an outpatient at referral hospital for TB in 
Macedonia-the Institute of lung diseases and 
tuberculosis. Initial examination of two sputum 
samples showed no presence of acid-fast bacilli (AFB) 
on fluorescence microscopy, but real-time PCR based 
molecular method (Xpert MTB/RIF; Cepheid, 
Sunnyvale CA, USA) confirmed the presence of 
Mycobacterium tuberculosis complex (MTBC) along 
with detection of RIF resistance (i.e. rpoB gene 
mutation). On patient’s request, both analyses were 
repeated 20 days later in another two samples of 
sputum, with the same result. By national guidelines 
and protocol, molecular analyses were extended to 
testing of susceptibility to isoniazid (INH) and 
subsequently to second-line anti-tubercular drugs, by 
using multiplex PCR-based reverse hybridisation Line 
Probe Assays (LPA). Both assays confirmed the 
presence of MTBC, revealing mutations of the rpoB, 
katG and InhA genes, i.e. RIF and INH resistance, as 
well as an absence of resistance to second-line anti-
tubercular drugs and ethambutol (GenoType MTBDR 
plus and GenoType MTDRsl, respectively; Hain 
Lifescience GmbH, Nehren, Germany). Patient’s 
illness was notified as MDR-TB, and the strain was 
considered to be multidrug-resistant. In the month that 
followed, Mycobacterium tuberculosis growth was 
verified with conventional methods in liquid and solid 
culture (Becton-Dickinson BACTEC MGIT 960 TB 
system, and Lӧwenstein Jensen medium, 
respectively). Resistance to the most important first-
line anti-tubercular drugs-RIF and INH- was confirmed 
by conventional phenotypic drug-susceptibility testing 
(DST), using the liquid-culture-isolate from the very 
first sputum sample (Table 1).  
Table 1: Microbiological analyses of sputum from the MDR-TB 
patient during 2016 (before and over the course of treatment) 
Date 
 
Sputum 
specimen 
             Conventional methods       Molecular methods 
  AFB 
smear 
micro-
scopy
a 
Solid  
medium
b 
Liquid 
medium
c 
 
Resistance 
pattern
d 
Xpert 
MTB/RIF 
VG4 
HAIN 
MTBDRplus 
V2.0 
HAIN   
MTBRsl 
 V1.0 
Apr 15 A
 
Negative 
 
Negative 
(result 
released 
on May 
31) 
 
Positive 
(result 
released on 
May 04) 
INH –R 
RIF - R 
EMB - S 
SM – S 
(result 
released on 
June 03)
e 
 
MTB 
detected, 
low;  
RIF 
resistant 
(rpoB) 
  
B
 
Negative 
 
Negative 
(result 
released 
on May 
31) 
 
     
May 04 A Negative 
 
Positive 
(2+) (result 
released 
on May 
31) 
Positive  
(result 
released on 
May 16) 
 MTB 
detected, 
low; RIF 
resistant 
(rpoB) 
INH –R  
(katG mut2) 
RIF – R  
(rpoB mut1) 
 
FLQ – 
S 
AG/CP 
– S 
EMB – 
S 
B Negative 
 
Negative 
(result 
released 
on May 
31) 
 
     
May 30 A Negative Positive 
(1+) (result 
released 
on Jul 18) 
Positive 
(result 
released on 
June 15) 
    
B Negative 
 
Positive 
(1+) (result 
released 
on Jul 18) 
     
Jun 30 A Negative Negative 
(result 
released 
on Aug 22) 
 
     
B Negative 
 
Negative  
(result 
released 
on Aug 22) 
 
     
Aug 22 A Negative Negative 
(result 
released 
on Oct 10) 
     
B Negative 
 
Negative 
(result 
released 
on Oct 10) 
 
     
Abbreviations: AFB = Acid Fast Bacilli; INH = isoniazid; RIF = rifampicin; EMB = ethambutol; SM = 
streptomycin; FLQ = fluorochinolones; AG = aminoglycozides; CP = cyclic peptides; MTB = Mycobacterium 
tuberculosis; A = early morning sputum; B = spot sputum specimen; R = resistant; S = sensitive; 
a
Auramine-
rhodamine staining for fluorescence microscopy (Merck, Darmstadt, Germany); 
b
Lӧwenstein Jensen 
medium; 
c
BACTEC MGIT 960 TB system (Becton-Dickinson); 
d
Phenotypic drug-susceptibility test (DST, 
conventional proportion method on Lӧwenstein Jensen medium); 
e
Resistance pattern from the isolate in 
liquid medium (Apr 15). 
 
Although the patient was repeatedly informed 
and advised about the seriousness of his health 
condition and health hazard for his family and 
community, it took a month and a half before obtaining 
consent and starting an appropriate anti-tubercular 
regimen. The major obstacles in this way were the 
stigma (i.e. denying the presence of disease) and 
behaved aggressively toward health care providers. At 
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hospital admission, the patient presented in good 
health condition, complaining only to rare productive 
cough. He had no personal or familial history of TB/TB 
treatment or known close contact, i.e. exposure to TB. 
Laboratory analyses showed only slightly raised 
erythrocyte sedimentation rate (ESR) of 36 mm in the 
first hour, without deviation in complete blood counting 
and routine blood analyses, and with HIV negative 
status. Chest X-ray revealed opacity with cavernous 
lesions in the right upper lobe (Figure 1).  
 
Figure 1: At hospital admission, opacity with cavernous lesions in 
the right upper lobe 
 
Following the guidelines of the World Health 
Organization (WHO), we started the so-called longer 
treatment of MDR-TB composed of at least five 
effective anti-tubercular drugs. Due to the patient’s 
strictly declining of parenteral drugs, we had to modify 
the regimen and conduct the intensive phase with 
three (instead of four) core second-line anti-tubercular 
drugs (levofloxacin, cycloserine, prothionamide) plus 
pyrazinamide and ethambutol (i.e. omitting the 
parenteral aminoglycoside) (Figure 2).  
 
Figure 2: Timetable of therapy 
 
After a month of directly observed therapy 
(DOT) and isolation in negative pressure room, two 
follow-up samples of sputum were again smear-
negative for AFB, sedimentation rate dropped into the 
normal range (6 mm in the first hour) and control 
chest X-ray showed no regression of changes. The 
patient was discharged from the hospital against 
medical advice and advised to continue the intensive 
phase of the regimen under ambulatory supervision 
(i.e. monthly control and take up of medicines in the 
Institute).  
Three months after the beginning of the 
treatment, he stopped making controls. The last 
available information provided by medical patronage 
system confirmed that he ceased the therapy early in 
December 2016. The only control after cessation took 
place in June 2017: routine laboratory analyses didn’t 
show any deviations, and microbiological examination 
of two sputum samples (smear microscopy, real-time 
PCR, liquid and solid medium culture) yielded no 
positive results. But, the changes in the right upper 
lobe on chest X-ray were still present, indicating the 
activity of the process (Figure 3). 
 
 
Figure 3: Six months after cessation of treatment: opacity with 
cavernous lesions and fibrotic changes in the right upper lobe 
 
 
 
Discussion 
 
This case report emerges several important 
issues pertinent to the overall management of MDR-
TB. 
Sputum smear microscopy is a commonly 
used test for diagnosis of pulmonary TB in low- and 
middle-income countries. In addition to the key 
disadvantage-the low sensitivity of 50-60% - it 
requires trained staff and at least two sputum samples 
to analyse while providing no information about drug 
resistance and distinction of non-tuberculous 
mycobacteria [14]. In the last decade, WHO set out 
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the efforts to establish infection control and overcome 
the problem with drug-resistant forms of TB, by 
implementing new molecular techniques for detection 
of Mycobacterium tuberculosis complex and drug 
resistance to anti-tubercular drugs. There are several 
molecular assays for rapid diagnosis of TB and 
determination of drug susceptibility profile, endorsed 
by WHO: Line Probe Assays (LPА) in 2008, and Xpert 
MTB/RIF assay in 2011 [10] [11]. Shortly after WHO 
approval, Ling, Zwerling and Pai conducted a meta-
analysis to evaluate the performance of most 
frequently used LPA-GenoType MTBDR [15]. 
GenoType MTBDR assays demonstrate excellent 
accuracy for rifampicin resistance (pooled sensitivity 
and specificity estimates of 98.1% and 98.7%, 
respectively). While specificity was excellent for 
isoniazid (99.5%), sensitivity estimates were modest 
and variable (84.3%). Similarly, the Cochrane review 
of 27 studies of adults with pulmonary TB, indicated 
that Xpert MTB/RIF is accurate for detecting rifampicin 
resistance, sensitive (95%) and specific (98%) [16]. 
Also, it is more accurate than smear microscopy for 
diagnosing TB: it is highly sensitive (89%), detecting 
almost all cases, and specific (99%). Authors 
concluded that Xpert MTB/RIF provides accurate 
results which can allow rapid initiation of MDR-TB 
treatment, pending results from conventional culture 
and DST. Likewise, the latest release of WHO Manual 
for Xpert MTB/RIF implementation (2014) contains an 
extended recommendation for implementing the Xpert 
MTB/RIF assay, i.e. to be used rather than 
conventional microscopy and culture as an initial 
diagnostic test in all adults suspected of having TB 
[17]. 
 Our case is a good confirmation of accuracy, 
precision and reproducibility of TB molecular 
diagnostic tests. Determined by two different 
molecular (genotyping) methods, drug resistance 
profile was identical in two separate sputum samples 
and subsequently confirmed by conventional DST. 
This gains importance when making therapy decision, 
especially if based only on conventional methods. Due 
to sputum low bacterial load (i.e. AFB negative on 
fluorescence microscopy), one should wait for the 
culture results (2-6 weeks) to start anti-tubercular 
therapy, and another 6 weeks to modify the regimen 
respecting the results of conventional DST. 
Conversely, molecular tests used in our case allow 
detection of MTB and RIF resistance in 2 hours, and 
detection of MTB and resistance to first-and second-
line anti-tubercular drugs in 24 hours [15] [18]. This 
emphasises the importance of molecular tests for the 
timely and accurate diagnosis of TB and resistance 
pattern, particularly in smear-negative microscopy [6] 
[8] [19] [20]. 
Drug resistance in MTBC is caused by 
mutations in restricted regions of its genome [21] [22]. 
As technical possibilities in our laboratory don’t allow 
sequencing of drug-resistance associated regions of 
MTBC genome and subsequent detailed description 
of mutations, detection is limited to mutations already 
included in molecular tests mentioned above. In terms 
of this, a clinician must count on occasional false-
positive RIF-resistance result on molecular test, which 
has to be promptly resolved as it seriously implicate 
therapy decision-to start first line anti-tubercular 
regimen and take the risk of resistance amplification 
to pyrazinamide and ethambutol, to conduct the 
lengthy and much more toxic MDR-TB treatment, or to 
defer starting any treatment while awaiting results of 
DST? [23] [24] [25] [26]. This complex problem could 
be overcome by advanced genotyping methods (DNA 
fingerprinting, whole genome sequencing). Studying 
the isolates at molecular level allows not only 
detection of MTBC and mutations in genes associated 
with drug resistance, but also discrimination between 
MTBC strains, distinction of co-infection with multiple 
strains, endogenous reactivation and exogenous re-
infection, existence of subpopulations with different 
resistance profiles, assessing the possible treatment 
failure, as well as clustering of isolates to particular 
genotype family databases (sequencing libraries from 
genomic DNA)-which may implicate pathogenesis, 
virulence, propensity to acquire resistance more easily 
under conditions of suboptimal treatment, and to 
spread in the community [27] [28] [29] [30] [31] [32] 
[33]. The importance of former molecular tools for 
epidemiological tracking in the community (i.e. 
detecting the sources of infection, pathways of spread 
of MTBC strains, distinct geographic distribution) is 
unequivocal and has made the worldwide designing of 
prevention and control strategies to block further 
transmission possible [34]. 
The low bacterial load in spot sputum 
samples shouldn’t underestimate the possibility of 
variable bacillary as a function of time, and so the 
persistence of the chain of infection [35]. Occasional 
sputum positivity in our patient is very likely, 
considering subjective sample collection for smear 
microscopy from a non-cooperative person. Moreover, 
due to negligent patient behaviour (postponing of 
hospital admission, shortening the regimen much 
earlier), we have to anticipate not only deterioration of 
his health condition over time, but the potential 
prolonged exposure of the environment to MDR-strain 
of Mycobacterium tuberculosis [18]. As the number of 
MDR-TB cases continues to rise worldwide, so does 
the amplification of MDR-TB strains during treatment. 
This amplification is generally assumed as a result 
from in vivo evolution of drug resistance caused by 
poor therapy compliance and/or inadequate treatment, 
considering the prior anti-TB treatment is a major risk 
factor associated with MDR-TB [7] [22] [36] [39]. 
Given the fact that our patient had no history of TB or 
TB treatment, nor he has other apparent risk factors 
or contacts for TB, it was reasonable to consider the 
case as TB with primary multidrug resistance [27] [28] 
[34] [40] [41]. To make the situation even more 
serious, our patient requested modification of 
intensive phase of the anti-tubercular regimen, and 
interrupted it early in the course, before initiation of 
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continuation phase. It has to be stressed that extreme 
non-adherence like this, could further compromise the 
infection control in an international context (i.e. 
continuous transmission of infection, additional 
acquisition of drug resistance via “amplification of 
resistance” and subsequent developing an XDR) [18] 
[34] [41].  
This emphasises the critical importance of 
clinical monitoring during DOT, introduced and 
recommended by WHO [30] [42]. However, there are 
some articles, mainly from the African continent, 
reporting on the successful alternative modality of 
treatment of smear-positive pulmonary TB and MDR-
TB instead of conventional DOT strategy. The 
essence of this home-based “family-member variant 
of DOT” approach, is to involve a reliably family-
member with responsibility of providing appropriate 
conditions (i.e. isolation, natural ventilation), supplying 
and directly supervising the taking of medicines on 
regular basis, and providing feedback about patient’s 
condition to his attending physician [43] [44]. Although 
this kind of practice is primarily related to resource-
limited settings and is not anticipated in current 
Program for TB control in Macedonia, it certainly 
deserves attention in future for extreme cases as we 
presented here. 
The previous issue raises the crucial ethical 
dilemma: how to deal with dual standards and protect 
the human rights of the minority (i.e. non-adherent TB 
patient)-at the expense of majority (i.e. community)? 
Patients generally have the right to refuse to follow 
professional medical advice. Those with infectious TB 
disease, however, “may lose the right to refuse such 
advice if health officials believe these persons are 
putting the public at risk for infection” [45]. There are 
rare situations where, despite all reasonable efforts, 
patients do not adhere to the prescribed course of 
treatment, or are unwilling or unable to comply with 
infection prevention and control measures. For such 
cases, the interests of other members of the 
community may justify efforts to isolate the patient 
involuntarily, by a pre-existing law or policy. WHO 
states that involuntary isolation should never be a 
routine component of TB-program. Involuntary 
isolation should be limited to exceptional 
circumstances, concerning infectiousness and non-
adherence of a patient to effective treatment, and after 
all reasonable measures to ensure adherence have 
been attempted and proven unsuccessful [46]. 
Governments have the legal authority to enact laws 
regarding infectious persons, and TB programs should 
develop policies in line with the guidance that clearly 
explains when and how involuntary isolation of TB 
patients is allowable. Some countries have already 
implemented the option for legal intervention, i.e. 
involuntary confinement in such cases [47] [48]. In our 
country, there is still no solution within the framework 
of existing legislation regarding involuntary isolation 
and compliance with the recommended combination 
of drugs, as well as interruption of therapy.  
In the transmission of resistant strains, the 
greatest individual risk factor is sharing living quarters 
with individuals who have defaulted on their treatment 
of TB or relapse cases [49]. Fortunately, close contact 
screening among household members (spouse, and 
two children aged 3 and 7) showed no presence of 
latent tuberculosis infection (LTBI) or active TB. 
Nevertheless, it raises the question of preventive 
treatment for contacts with MDR-TB, especially when 
children involved in this problem, as well as the 
duration of the follow-up period. The current modest 
recommendation reflects the limited quality of 
evidence and comes down to strict clinical observation 
and close monitoring for the development of active TB 
for at least two years for contacts with MDR-TB cases 
[50].  
In conclusion, the benefit of molecular tests in 
the early diagnosis of TB and drug resistance is 
unequivocal for adequate and in time treatment of 
resistant forms of TB. Whole genome sequencing of 
pathogens, also, is becoming part of routine practice 
for establishing resistance patterns and transmission 
tracking. To sum up, the current comprehensive 
technology has the power to clarify our understanding 
of the links in MDR-TB transmission between low- and 
high-incidence areas. Given these points, our report 
implies that MDR-TB represents not just a regional 
epidemic in some parts of the world, but also a 
challenge to international health, including countries 
with low prevalence of MDR-TB. Knowledge of 
circulating strains and their resistance patterns is 
essential to developing effective TB control programs 
within occupational health, to curtail the transmission 
of TB in the country and the region. The greater 
certainty of transmission data can provide evidence to 
justify more active policies of screening and isolation 
as part of infection control. Increased vigilance for TB 
among workers whose job description includes 
frequent border crossing should be surely taken into 
consideration as a part of these screening policies. 
Finally, we believe an urgent need is existing for in-
depth discussion between medical and legal 
authorities about the problem of involuntary 
confinement and enforced treatment of non-adherent 
patients. While waiting for the legal resolution of this 
ethical and social problem, clinicians should consider 
alternative modalities for the successful treatment of 
patients with MDR-TB and protect the patients 
themselves, their families and the community. 
Regarding this, foreign experience in home-based 
DOT could be adapted to local conditions and would 
be a good starting point in moving forward.  
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